Phase II trial of piroxantrone in metastatic breast cancer. A Southwest Oncology Group study.

Abstract

Thirty-two eligible patients with advanced metastatic breast cancer who had received no more than 1 prior chemotherapy regimen for metastatic disease (16 had received prior doxorubicin) were treated with piroxantrone at a dose of 120 mg/m2 intravenously every 21 days. In the twenty-seven patients evaluable for response, two partial responses were seen. Toxicities observed were primarily hematologic with grade 3 or greater granulocytopenia occurring in 34% of the patients. One patient developed symptomatic congestive heart failure at a total cumulative dose of 960 mg/m2. We conclude that piroxantrone given at this dose and schedule has minimal activity in patients with metastatic breast cancer.

• Authors: P M Ravdin, S Green, J H Doroshow, S Martino
• Journal: Investigational new drugs (Invest New Drugs) Vol. 12 Issue 4 Pg. 333-6 ( 1994) ISSN: 0167-6997 [Print] United States
• PMID: 7775136 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Anthraquinones
• Antineoplastic Agents
• Pyrazoles
• piroxantrone

Topics

• Adenocarcinoma (drug therapy, secondary)
• Adult
• Aged
• Anthraquinones (adverse effects, therapeutic use)
• Antineoplastic Agents (adverse effects, therapeutic use)
• Breast Neoplasms (drug therapy, pathology)
• Humans
• Middle Aged
• Pyrazoles (adverse effects, therapeutic use)